B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on MiNK Therapeutics (INKT – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.72.
According to TipRanks, Mamtani is an analyst with an average return of -12.4% and a 30.30% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Agenus, and Altimmune.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiNK Therapeutics with a $7.00 average price target, which is a 306.98% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
INKT market cap is currently $57.83M and has a P/E ratio of -2.35.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INKT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
Read More on INKT:
- MiNK’s Novel FAP-CAR-iNKT Presented at ASGCT
- MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
- MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
- MiNK Therapeutics announces clinical data of allogeneic iNKT cells
- MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
